Sterilization Validation Failures Exposed in Recent FDA Letters

Strategic Insights -

The US Food and Drug Administration (FDA) issued warning letters to three pharmaceutical companies, Gensia Sicor, Medi-Physics, and TMED, citing failures in sterilization validation. The letters highlight critical issues in process validation, equipment sanitization, and quality control procedures. The inspection and subsequent letters demonstrate the FDA's focus on ensuring the safety and efficacy of pharmaceutical products.

Key Takeaways:

  • Gensia Sicor was cited for failure to establish procedures to ensure equipment and utensils are sanitized at appropriate intervals, potentially leading to contamination of drugs.
  • Medi-Physics was found to have insufficient evidence demonstrating the validity of its sanitizing processes for production equipment and areas, putting the quality and purity of radiopharmaceutical products at risk.
  • TMED's facility in Columbia, TN, was inspected for issues related to EtO sterilization procedure validation, distribution of non-sterilized products, and potential underlying problems in quality control procedures.
  • All three companies faced FDA warnings, which included requests for revised Standard Operating Procedures (SOPs) and implementation of corrective actions to address the identified issues.
  • Revised SOPs were submitted by Gensia Sicor, and the agency concluded that the warning letter was resolved in August.
  • The FDA removed holds on Gensia's ANDA (Abbreviated New Drug Application) in August, indicating a positive outcome for the company.
  • NYcomed Amersham Imaging was instructed to arrange for a consultant audit and certification of its manufacturing and quality assurance programs as a condition for resuming marketing clearance.
  • The companies were given specific instructions to address the identified issues, with some submitting corrective action plans and estimated completion dates for the required changes.

Statistics:

  • 3 pharmaceutical companies received FDA warning letters for sterilization validation failures.
  • The letters cited failures in equipment sanitization (Gensia Sicor), process validation (Medi-Physics), and quality control procedures (TMED).
  • 2 lots of products were referenced in the TMED letter as potentially non-sterilized.
  • The FDA found deficiencies in performance qualification (Medi-Physics) and standard operating procedures (TMED).
  • Revised SOPs were submitted by Gensia Sicor, and the agency concluded that the warning letter was resolved in August.
  • The FDA removed holds on Gensia's ANDA in August.

Sources:

  • Doc. 7876W - FDA warning letter to Gensia Sicor, dated July 21.
  • Doc. 7884W - FDA warning letter to Medi-Physics, dated June 4.
  • Doc. 7922W - FDA warning letter to TMED, dated July 1.